The transaction's two focuses, Palsonify and atumelnant, have combined peak sales potential of more than $5 billion, Vertex ...

Vertex Pharmaceuticals will spend $10 billion to acquire Crinetics Pharmaceuticals and its drug for a rare endocrine disorder ...

This buy gives Vertex both a recently-commercialized drug, and a very strong lead candidate.

Vertex Pharmaceuticals Incorporated’s $10B Crinetics Pharmaceuticals, Inc. buy adds PALSONIFY & a Phase 3 CAH asset. Click ...

Additional blockbuster drugs may be on the horizon.

Vertex Pharma has claimed an ultra-fast approval in the US for Trikafta, its three-drug combination that provides a treatment option for up to 90% of patients with the genetic disease cystic fibrosis.

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta thalassaemia and sickle cell disease in an early-stage trial ...

This price reflects trading activity during the overnight session on the Blue Ocean ATS, available 8 PM to 4 AM ET, Sunday through Thursday, when regular markets are closed. The above button links to ...

A line graph is used to spot trends in data over time. In order to produce a line graph, data is required. The data often comes in the form of a table. A student recorded how much time they spent ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

With nearly two decades of retail management and project management experience, Brett Day can simplify complex traditional and Agile project management philosophies and methodologies and can explain ...

Vertex Pharmaceuticals is buying an endocrine treatment specialist for $10 billion.